Given DNMT3A R882 mutations are acquired early in the precursors of MNs, significantly higher fractions of DNMT3A R882 mutations in AML than MDS in our study suggests that these mutations may confer higher risk of developing AML than non-R882 mutations. This evidence concerns the gene DNMT3A and acute myeloid leukemia.